This article first appeared on GuruFocus. Hims & Hers Health (NYSE:HIMS) faces a more complicated growth path as regulatory pressure reshapes its weight-loss business, prompting JPMorgan to resume coverage at Neutral with a $32 price target. The target implies roughly 17% upside from the Sept. 10 close, but the bank wants clearer evidence that Hims can successfully transition from compounded GLP-1 drugs toward branded treatments without sacrificing margins. Warning! GuruFocus has detected 5 Warning Signs with HIMS. Is HIMS fairly valued? Test your thesis with our free DCF calculator.
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.